
Please try another search
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 expressing solid tumors. It also develops CHM CORE-NK that is in phase Ia/IIb clinical trials for acute myeloid leukaemia/colorectal cancer and acute myeloid cancer, as well as in preclinical trials for blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Name | Age | Since | Title |
---|---|---|---|
Paul Edward-Alexander Hopper | 67 | 2020 | Founder & Executive Chairman |
Lesley Russell | 63 | 2020 | Non-Executive Director |
Stanley Frankel | - | - | Member of Cellular Immunotherapy Scientific Advisory Board |
Phillip Allen Hains | 65 | 2020 | CFO, Joint Company Secretary & Director |
Eric Smith | - | 2021 | Member of Cellular Immunotherapy Scientific Advisory Board |
Michael R. Bishop | - | 2021 | Member of Cellular Immunotherapy Scientific Advisory Board |
Eric M. Sullivan | 45 | 2023 | Non-Executive Director |
David G. Maloney | - | 2021 | Member of Cellular Immunotherapy Scientific Advisory Board |
H. Miles Prince | - | 2025 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review